ID   H938
AC   CVCL_D536
DR   cancercelllines; CVCL_D536
DR   ChEMBL-Cells; CHEMBL3307889
DR   ChEMBL-Targets; CHEMBL614161
DR   HIVReagentProgram; ARP-1298
DR   PubChem_Cell_line; CVCL_D536
DR   Wikidata; Q54872251
RX   PubMed=3422113;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C3366; Sezary syndrome
DI   ORDO; Orphanet_3162; Sezary syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1240 ! H9
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 17
//
RX   PubMed=3422113; DOI=10.1126/science.3422113;
RA   Felber B.K., Pavlakis G.N.;
RT   "A quantitative bioassay for HIV-1 based on trans-activation.";
RL   Science 239:184-187(1988).
//